Dataset Information

Increasing Natural Resistance Associated Macrophage Protein 1 serum level after Miana treatment in BALB/c induced Klebsiella pneumoniae experimental research.

ABSTRACT:

Background

Miana (Coleus Scutellariodes [L] Benth) inhibits growth of bacterial pathogen inside macrophage.

Objective

The aim of this study is to determine the protein level of Natural Resistance Associated Macrophage Protein 1 (NRAMP1), after administration of Miana extracts in BALB/c mice induced Klebsiella pneumoniae.

Methods

This is an experimental study using animal model with post test-only controlled group design. Twenty healthy adult male BALB/c mice were randomly divided into four groups, negative control group (distilled water), Levofloxacin 100 mg/kg, injection intraperitoneal, first treatment group (Miana leaves extract/MLE 510 mg/kg) and second treatment group (Miana + levofloxacin). MLE were administered via gastric gavage for ten consecutive days. The blood was drawn from each mice on the first day, on the eight day of experiment (2 h after treatment), and at 10 days. The blood sample was examined by ELISA to determine the NRAMP1 protein level. Analysis of the number of lung tissue bacteria used Plate count agar to see the growth of Klebsiella pneumonia.

Results

NRAMP1 protein level in BALB/c mice after administration of Miana extract was increased significantly in after 10 days treatment (p < 0.0001). The highest increasing in protein levels was found in treatment group (Miana + levofloxacin) with an increase before treatment 3036,07 to 10010,30 pg/ml after treatment p < 0,0001.

Conclusion

NRAMP1 protein level in BALB/c mice were highest increasing in protein levels after administration of Miana extract and Levofloxacin compared Miana or Levofloxacin only and clinical impact proved a comparable effect on suppressing Klebsiella pneumoniae growth.The institutional protocol number of this study is 1010/UN4.6.4.5.31/PP36/2019.

SUBMITTER: Wahyuni TD

PROVIDER: S-EPMC8058902 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:The aim of this study was to determine whether there is an association between serum resistance, O serotypes, and the production of extended-spectrum beta-lactamases (ESBLs) in Klebsiella pneumoniae. Ninety ESBL-producing and 178 non-ESBL-producing K. pneumoniae isolates gathered in five European countries were O serotyped and tested for sensitivity to the serum's bactericidal effect. The frequency of serum-resistant isolates was higher among ESBL-producing strains (30%; 27/90 isolates) than among non-ESBL-producing strains (17.9%; 32/178 isolates) (P = 0.037; odds ratio [OR] = 1.96; 95% confidence interval [95% CI] = 1.08 to 3.53). Although O1 was the most common O serotype in both Klebsiella groups, its frequency among ESBL-producing strains was significantly higher (59%; 53/90 isolates) than among non-ESBL producers (36%; 64/178 isolates) (P = 0.0006; OR = 2.5; 95% CI = 1.52 to 4.29). Furthermore, the prevalence of the O1 serotype was higher among serum-resistant strains of both ESBL-producing (74%; 20/27isolates) and non-ESBL producers (75%; 24/32 isolates) than among serum-sensitive ESBL producers (52.4%; 33/63 isolates) and non-ESBL producers (27.4%; 40/146 isolates). Serum resistance among ESBL-producing strains (36%; 17/47 isolates) versus non-ESBL-producing strains (16%; 27/166 isolates) was also significantly higher after the exclusion of clonal strains (P = 0.0056; OR = 2.9; 95% CI = 1.41 to 6.01). Sixteen ESBL types were detected, among which the frequency of serum resistance was significantly lower among the SHV-producing strains (9/48 isolates) than among the TEM producers (16/35 isolates) (P = 0.016; OR = 3.65; CI = 1.3 to 9.7). Curing ESBL-coding plasmids did not influence the serum resistance of the bacteria; all six plasmid-cured derivatives maintained serum resistance. The present findings suggest that ESBL-producing strains have a greater pathogenic potential than non-ESBL-producing strains, but the linkage between O serotypes, serum resistance, and ESBL production remains unclear at this stage.